ATOS — Atossa Genetics Inc
NASDAQ · Healthcare · Biotechnology
$2.40
-$0.02 (-0.83%)
Atossa Genetics Inc (ATOS) is a biotechnology company listed on NASDAQ. It is led by Steven C. Quay FCAP, M.D., Ph.D., based in 107 Spring Street, Seattle, WA, United States, 98104, with about 15 employees. Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
Net income was -$8.7M. ATOS currently screens at market cap $121.2M.
Use this ATOS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ATOS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ATOS SEC filings page. Lician reads the product cache first so this HTML stays unique to Atossa Genetics Inc even when a live quote feed is slow.
About Atossa Genetics Inc
Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company that develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is based in Seattle, Washington.
ATOS Key Statistics
Market Cap
$121.23M
Volume
21,871
Previous Close
$2.65
Day Range
$2.58 – $2.69
EPS
-$0.20
Revenue
$0.00
Net Income
-$25.50M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
15
ATOS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$25.50M | -$30.09M | -$26.96M | -$20.61M |
| EPS (Diluted) | -$0.20 | -$0.24 | -$0.21 | $0.00 |
Total Assets
$76.44M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$71.08M
Operating Cash Flow
-$21.03M
Free Cash Flow
$0.00
Atossa Genetics Inc Company Information
- Chairman, CEO & President
- Steven C. Quay FCAP, M.D., Ph.D.
- Headquarters
- 107 Spring Street, Seattle, WA, United States, 98104
- Website
- www.atossatherapeutics.com
- Phone
- 206-588-0256
- IPO / Founded
- 2012-11-08
- Sector
- Healthcare
- Industry
- Biotechnology